“The CAFC ultimately found that Novartis’ patent’s lack of description for a complexed form of valsartan and sacubitril ‘does not affect the validity of the patent’ because that complex, which wasn’t ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback